

ANTIMICROBIAL SUSCEPTIBILITY PATTERNS 2019

Produced by the Microbiology Department
Canterbury Health Laboratories, Canterbury DHB

Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2019

Organism Name	Number tested	Antibiotics in common use (1st line reporting)								Reserved (2nd line reporting)				Topical			
		Ampicillin/ amoxicillin	Penicillin	MethFlucloxacillin	Erythromycin	Clindamycin #	Genamycin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim-sulfamethoxazole	Fusidic Acid #	TetraDoxycycline	Ciprofloxacin #	Vancomycin #	Chloramphenicol	Mupirocin (High-Level)	
<i>S. aureus</i> (not MRSA)	3988		19	100*	90	91	98		94	97	92	98	97	100		99	99
MRSA	360		0	0	73	82	88			88	79	94	78	100		96	99
<i>S. epidermidis</i>	337		0	39	37	65			25	47	56	90	64	100			
<i>S. saprophyticus</i>	152	96		98					100	95	96			100			
<i>Enterococcus faecalis</i>	639	100 ^b							100			100		100			
<i>Enterococcus faecium</i>	108	15												94			
<i>Streptococcus pneumoniae</i>	243	96*	96*		78	88*				80		79		100			
<i>Streptococcus</i> Grp A	67	100	100		92	95				97		69*		100			

Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2019

Organism Name	Number tested	Antibiotics in common use (1st line reporting)								Reserved (2nd line reporting)						
		Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin	Genamycin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim-sulfamethoxazole	Tetracycline	Ceftaxone	Piperacillin-Tazobactam [§]	Cefepime [#]	Mergaenam [#]	Fosfomycin [#]	Ciprofloxacin [#]
<i>Citrobacter freundii</i> complex	75	0	0	0	0	97	0	95	96		77	84	97	100	99	96
<i>Citrobacter koseri</i>	92	0	99	100	100	100		99	99		100	100	100	100	100	100
<i>Enterobacter cloacae</i> complex	200	0	0	0	0	97	0	81	88		74	77	95	100	84	95
<i>Enterobacter aerogenes</i>	53	0	0	0	0	98	0	97	98		75	76	100	100	98	96
<i>Escherichia coli</i>	4834	52	69	89	92	95	99	76	78		93	98	95	100	100	88
<i>Klebsiella oxytoca</i>	186	0	86	86	86	100		98	98		91	90	100	100	95	99
<i>Klebsiella pneumoniae</i>	516	0	87	85	91	97	0	86	86		93	94	94	100	92	90
<i>Morganella morganii</i>	62	0	0	0	0	89	0	70	81		98	98	100	100	23	84
<i>Proteus mirabilis</i>	270	86	96	97	95	64	0	86	89		99	100	99	100	95	96
<i>Serratia marcescens</i>	98	0	0	0	0	97	0	96	99		87	87	98	100	95	89
<i>Pseudomonas aeruginosa</i>	709	0	0	0	0	95	0	0	0		0	97	94	98		90
<i>Acinetobacter baumannii</i> complex	40	0	0	0	0	72	0	0	94		0			93	0	92
<i>Haemophilus influenzae</i>	691	62	91	55				71	99							94
<i>Moraxella catarrhalis</i>	195	1	98	100				97	100							100*

Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from Urinary Tract Infections: 2019

Organism Name	Number tested	Antibiotics in common use (1st line reporting)								Reserved (2nd line reporting)						
		Ampicillin/Amoxicillin	Amoxicillin-Clavulanate	Cefalexin	Genamycin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim-Sulfamethoxazole	Tetracycline	Ceftaxone	Piperacillin-Tazobactam [§]	Cefepime [#]	Mergaenam [#]	Fosfomycin [#]	Ciprofloxacin [#]	
<i>Citrobacter freundii</i> complex	62	0	0	0	98	0	98	98		82	89	100	100	98	97	
<i>Citrobacter koseri</i>	73	0	100	100	100		99	99		100	100	100	100	100	100	
<i>Enterobacter cloacae</i> complex	119	0	0	0	97	0	81	86		76	79	96	100	84	95	
<i>Enterobacter aerogenes</i>	37	0	0	2	100	0	97	97		73	74	100	100	94		
<i>Escherichia coli</i>	4245	55	70	82	95	99	76	79		96	99	97	100	100	90	
<i>Klebsiella oxytoca</i>	120	0	88	86	100		98	99		93	91	100	100	96	99	
<i>Klebsiella pneumoniae</i>	391	0	90	91	99	0	87	90		97	96	98	100	92	94	
<i>Morganella morganii</i>	45	0	0	0	89	0	73	77		98	98	100	100	26	84	
<i>Proteus mirabilis</i>	244	86	96	95	63	0	86	90		100	100	100	100	95	96	
<i>Serratia marcescens</i>	54	0	0	0	94	0	98	98		79	77	98	100	94	85	

* Tested on 10- 30 isolates

S. aureus susceptible to methicillin/flucloxacillin denotes susceptibility to ceftazolin and amoxicillin-clavulanate

§ *Enterococcus* species are intrinsically resistant to cephalosporins

° Includes Intermediate (Susceptible, Increased Exposure) results

^d Treatment of uncomplicated urinary tract infections only

Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g.

§ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document this in the clinical notes) unless following a CDHB anti

No data or not tested

Colour Interpretation

≥ 90% Susceptible

70 - 89% Susceptible

< 70% Susceptible